The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Novel treatment modalities emerging for WM: bispecifics, CAR T-cells & combinations with BTKis
In this video, Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares promising novel treatment approaches being explored in Waldenström’s macroglobulinemia (WM), including bispecific antibodies and CAR T-cells. Dr Treon further comments on the potential of combining BTK inhibitors (BTKis) with bispecifics to ameliorate adverse events. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, we’re very excited about bispecific antibodies as well as CAR T-cells. For me, really, the advent of seeing the activity of bispecifics and other related disease groups has me excited. We just actually opened a trial with epcoritamab in Waldenstrom’s at our center. There’s also a similar study taking place in Europe. I do see other assets, particularly those that we just learned about here at ICML, also moving to Waldenstrom’s...
Yeah, we’re very excited about bispecific antibodies as well as CAR T-cells. For me, really, the advent of seeing the activity of bispecifics and other related disease groups has me excited. We just actually opened a trial with epcoritamab in Waldenstrom’s at our center. There’s also a similar study taking place in Europe. I do see other assets, particularly those that we just learned about here at ICML, also moving to Waldenstrom’s. And being able to actually leverage BTK inhibitors in combination with bispecifics has me excited because we have the potential to ameliorate CRS and ICANS with BTK inhibitors. We might also be able to reverse some of the T-cell exhaustion. And so I do see really a future where what we’ve learned from the past, particularly BTK inhibition, might offer for the future in combination with cellular therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
